ADMA Biologics Inc (OQ:ADMA)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: C/O Adma Biologics
Inc., 465 State Route 17
RAMSEY NJ 07446
Tel: N/A
Website: https://www.admabiologics.com
IR: See website
<
Key People
Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Brian Lenz
Chief Financial Officer, Executive Vice President
Business Overview
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Financial Overview
For the fiscal year ended 31 December 2023, ADMA Biologics Inc revenues increased 68% to $258.2M. Net loss decreased 57% to $28.2M. Revenues reflect ADMA BioManufacturing segment increase of 73% to $249.7M, Corporate segment remaining flat at $143K, United States segment increase of 67% to $244.9M, International segment increase of 74% to $13.3M.
Employees: 624 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,617M as of Dec 31, 2023
Annual revenue (TTM): $258.22M as of Dec 31, 2023
EBITDA (TTM): $29.96M as of Dec 31, 2023
Net annual income (TTM): -$28.24M as of Dec 31, 2023
Free cash flow (TTM): $3.82M as of Dec 31, 2023
Net Debt Last Fiscal Year: $79.24M as of Dec 31, 2023
Shares outstanding: 228,220,236 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.